JP2011526608A5 - - Google Patents

Download PDF

Info

Publication number
JP2011526608A5
JP2011526608A5 JP2011515493A JP2011515493A JP2011526608A5 JP 2011526608 A5 JP2011526608 A5 JP 2011526608A5 JP 2011515493 A JP2011515493 A JP 2011515493A JP 2011515493 A JP2011515493 A JP 2011515493A JP 2011526608 A5 JP2011526608 A5 JP 2011526608A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
heparin
composition according
ulcer
life
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011515493A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011526608A (ja
Filing date
Publication date
Priority claimed from ES200802002A external-priority patent/ES2340902B1/es
Application filed filed Critical
Publication of JP2011526608A publication Critical patent/JP2011526608A/ja
Publication of JP2011526608A5 publication Critical patent/JP2011526608A5/ja
Pending legal-status Critical Current

Links

JP2011515493A 2008-07-01 2009-06-30 グリコサミノグリカンを含む医薬組成物及び慢性潰瘍の処理へのその使用 Pending JP2011526608A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ESP200802002 2008-07-01
ES200802002A ES2340902B1 (es) 2008-07-01 2008-07-01 Composicion farmaceutica con glicosaminoglicanos y su uso en tratamiento de ulceras cronicas.
PCT/ES2009/070264 WO2010000904A1 (es) 2008-07-01 2009-06-30 Composición farmacéutica con glicosaminoglicanos y su uso en tratamiento de úlceras crónicas

Publications (2)

Publication Number Publication Date
JP2011526608A JP2011526608A (ja) 2011-10-13
JP2011526608A5 true JP2011526608A5 (enExample) 2014-08-07

Family

ID=41319881

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011515493A Pending JP2011526608A (ja) 2008-07-01 2009-06-30 グリコサミノグリカンを含む医薬組成物及び慢性潰瘍の処理へのその使用

Country Status (15)

Country Link
US (2) US20110201572A1 (enExample)
EP (1) EP2308497B1 (enExample)
JP (1) JP2011526608A (enExample)
CN (1) CN102176915A (enExample)
AU (1) AU2009265623B2 (enExample)
BR (1) BRPI0913839A2 (enExample)
CA (1) CA2766483C (enExample)
CY (1) CY1115780T1 (enExample)
DK (1) DK2308497T3 (enExample)
ES (2) ES2340902B1 (enExample)
MX (1) MX2010014552A (enExample)
PL (1) PL2308497T3 (enExample)
PT (1) PT2308497E (enExample)
RU (1) RU2011103459A (enExample)
WO (3) WO2010000906A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2357601B1 (es) * 2011-01-26 2012-03-21 Laboratorios Farmacéuticos Rovi, S.A. Procedimiento de preparación de derivados de glicosaminoglicanos donadores de óxido n�?trico y su uso en tratamiento de úlceras crónicas.
JP2012245943A (ja) * 2011-05-31 2012-12-13 Hitachi Automotive Systems Ltd 制御装置
JP5942133B2 (ja) * 2012-09-11 2016-06-29 学校法人関西文理総合学園 蛍光プローブ及びこれを用いた酵素活性検出方法
KR20170123345A (ko) * 2015-03-20 2017-11-07 오르후스 우니베르시테트 지질단백질 대사 장애의 치료를 위한 pcsk9의 억제제
EP3273239A1 (en) 2016-07-19 2018-01-24 Laboratorios Farmacéuticos Rovi, S.A. Procedure of analysis of glycosaminoglycans, heparins and their derivatives by nuclear magnetic resonance
JP7333919B2 (ja) * 2017-09-05 2023-08-28 エクセル メッド、エルエルシー 虚血を治療するためのヘパリン組成物
ES2792298B2 (es) * 2020-04-27 2022-04-20 Farm Rovi Lab Sa Procedimiento para la obtencion de heparinas de bajo peso molecular y heparinas de bajo peso molecular obtenidas por el mismo

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6004A (en) * 1849-01-09 chinnqck
NL7808292A (nl) * 1977-08-08 1979-02-12 Choay Sa Heparine-preparaten vrij van minerale zouten, in het bijzonder oxalaten, en een werkwijze ter bereiding daarvan.
CA1136620A (en) * 1979-01-08 1982-11-30 Ulf P.F. Lindahl Heparin fragments having selective anticoagulation activity
FR2482611B1 (fr) * 1980-05-14 1986-03-07 Pharmindustrie Nouveaux polysaccharides sulfates, procedes pour leur preparation et leur utilisation comme medicaments
IT1245907B (it) * 1991-05-17 1994-10-25 Alfa Wassermann Spa Uso dei glicosaminoglicani nel trattamento della nefropatia diabetica e della neuropatia diabetica.
CA2310422A1 (en) * 1997-11-20 1999-06-03 Ikuo Yamashina Low-molecular heparin modification and remedy for skin ulcer
ES2161615B1 (es) * 1999-07-23 2003-03-16 Rovi Lab Farmaceut Sa Composiciones de heparinas de muy bajo peso molecular.
WO2002077155A2 (en) 2001-01-08 2002-10-03 Human Genome Sciences, Inc. Keratinocyte growth factor-2
CU23043A1 (es) 2001-12-20 2005-05-20 Ct Ingenieria Genetica Biotech Composicion farmaceutica que contiene factor de crecimiento epidrmico (egf) para la prevencion de la amputacion de pie diabetico.
AU2003219421A1 (en) 2002-05-02 2003-11-17 Pfizer Products Inc. Treatment of diabetes and diabetic complications with nhe-1 inhibitors
US20060040896A1 (en) * 2004-08-18 2006-02-23 Paringenix, Inc. Method and medicament for anticoagulation using a sulfated polysaccharide with enhanced anti-inflammatory activity
CU23388B6 (es) 2006-01-31 2009-07-16 Ct Ingenieria Genetica Biotech Composición farmacéutica de microesferas para prevenir la amputación del pie diabético

Similar Documents

Publication Publication Date Title
JP2011526608A5 (enExample)
WO2009029622A3 (en) Antiviral drugs for treatment of arenavirus infection
NO20084919L (no) Oksadiazolidindionforbindelse
CY1121853T1 (el) Συνδυαστικη θεραπεια για την αγωγη του διαβητη
CY1115350T1 (el) Χρησεις αναστολεων της dpp iv
MX359989B (es) Fármacos antivirales para el tratamiento de la infección por arenavirus.
MY149622A (en) Pyrazoles as 11-beta-hsd-1
JP2013518056A5 (enExample)
JP2016530291A5 (enExample)
EA201200968A1 (ru) Применение транс-кломифена для предотвращения или лечения диабета 2 типа у мужчин
TNSN07413A1 (en) Use of tfpi to treat severe bacterial infections
UA113849C2 (xx) Застосування сигма-лігандів при болю, пов'язаному з діабетом 2 типу
JP2017014206A5 (enExample)
TN2009000275A1 (en) Use of substituted pyranone acid derivatives for the treatment of metabolic syndrome
CY1115780T1 (el) Φαρμακευτικη συνθεση με glycosαμινοglycans και χρηση αυτης για την θεραπεια χρονιων ελκων
JP2018172440A5 (enExample)
PH12014502802B1 (en) Novel compound having ability to inhibit 11b-hsd1 enzyme or pharmaceutically acceptable salt thereof, method for producing same, and pharmaceutical composition containing same as active ingredient
TN2010000266A1 (en) Oxazolidinones for the treatment and/or prophylaxis of heart failure
UA88941C2 (ru) Замещенные 4-фенилтетрагидроизохинолины, их применение как лекарственных средств, а также лекарственные средства, которые их содержат
UY32670A (es) Utilizacion de alfa -1-antitripisina para la preparacion de medicamentos para el tratamiento del sindrome de fatiga cronica
RU2008117303A (ru) Применение активаторов растворимой гуанилатциклазы для лечения острых и хронических легочных заболеваний
JP2011012060A5 (enExample)
WO2005007239B1 (es) Uso de la dapsona como neuroprotector en el infarto cerebral
ATE527997T1 (de) Verwendung von aminapthon zur herstellung eines medikaments zur behandlung von arteriopathien
BR112013028698A8 (pt) Compostos para uso no tratamento de infecções retrovirais em felinos